Lenvatinib — Drug Intelligence | 60 EU Trials

Filter these 60 trials by condition, phase, country and more.

Open in Search →

60 Registered trials

15 Recruiting

42 Completed trials

28 Sponsors

22 Countries

Phase III

Phase II

Phase I/II

Phase III: 14 Phase II/III: 1 Phase II: 27 Phase I/II: 12 Phase III/IV: 1 Phase IV: 1 Phase I (Other): 2 Phase I (FiH): 1 Other: 1

Oversight events:

2 serious breaches 4 temporary halts 2 urgent safety measures 2 unexpected events across 8 trials

View oversight register →

Indications tested

Hepatocellular carcinoma 7 Colorectal cancer 4 Renal cell carcinoma 4 Endometrial cancer 3 Ovarian cancer 2 Small cell lung cancer extensive stage 2 Triple negative breast cancer 2 Non-small cell lung cancer 2 Ewing's sarcoma recurrent 1 Extra-osseous Ewing´s sarcoma metastatic 1 Hepatic cancer 1 Laryngeal squamous cell carcinoma 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 26 AstraZeneca AB 3 Eisai Limited 3 Assistance Publique Hopitaux De Paris 2 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 2 Institut Gustave Roussy 2 AbbVie Deutschland GmbH & Co. KG 1 AGO Research GmbH 1 Bluepharma Industria Farmaceutica S.A. 1 Bristol-Myers Squibb Services Unlimited Company 1 CatalYm GmbH 1 Centre Hospitalier Universitaire De Bordeaux 1

All trials — page 2

60 total

A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended

2023-507687-38-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended

2023-503905-12-00 Phase II 4 countries Merck Sharp & Dohme LLC
A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for… Ended

2024-514207-34-00 Phase III 2 countries Shanghai Junshi Biosciences Co. Ltd.
An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended

2022-502122-41-00 Phase III 14 countries Merck Sharp & Dohme LLC
Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended

2024-510620-39-00 Phase III 13 countries Merck Sharp & Dohme LLC
PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA). Ended

2024-516618-39-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in C… Ended

2023-509604-15-00 Phase I (Other) 2 countries AstraZeneca AB
A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended

2023-506839-15-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HC… Ended

2023-508635-31-00 Phase III 8 countries Bristol-Myers Squibb Services Unlimited Company
Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on … Ended

2024-513027-16-00 Phase II 1 country Institut Gustave Roussy
Study of Avelumab in combination with Lenvatinib for children with primary CNS tumors Halted

2024-512940-51-00 Phase I (Other) 2 countries Merck Healthcare KGaA
Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular car… Ended

2024-516408-40-00 Phase I/II 1 country Assistance Publique Hopitaux De Paris
A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended

2023-505022-34-00 Phase II 4 countries Merck Sharp & Dohme LLC
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects Ended

2022-501327-25-00 1 country Bluepharma Industria Farmaceutica S.A.
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo… Ended

2024-511750-53-00 Phase I (FiH) 2 countries Salubris Biotherapeutics Inc.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Ended

2023-505425-14-00 Phase I/II 1 country Eisai Limited
SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refra… Ended

2024-515731-29-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended

2023-505284-36-00 Phase II 6 countries Merck Sharp & Dohme LLC
Phase 2 First-Line ES-SCLC Platform Study Ended

2023-506538-56-00 Phase II 5 countries Merck Sharp & Dohme LLC
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended

2022-501342-29-00 Phase III 6 countries Merck Sharp & Dohme LLC
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular C… Ended

2023-505698-34-00 Phase II 3 countries Merck Sharp & Dohme LLC
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain M… Ended

2023-506315-17-00 Phase I/II 6 countries Merck Sharp & Dohme LLC
“A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatini… Ended

2023-508001-25-00 Phase II 3 countries Medica Scientia Innovation Research S.L.
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga… Ended

2023-504834-23-00 Phase III/IV 7 countries Merck Sharp & Dohme LLC

Showing 25–48 of 60 trials

← All drugs A–Z